帕金森病中的视觉幻觉:聚焦中央胆固醇功能障碍
Anna Ignatavicius1, Elie Matar1,2,3, Simon J G Lewis4,5
1Faculty of Medicine and Health, Central Clinical School, University of Sydney, Sydney, NSW 2050, Australia.
Brain : a journal of neurology
|September 10, 2024
概括
帕金森病中的视觉幻觉与大脑变化有关. 胆固醇系统功能障碍是关键因素,为治疗提供了新的途径.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
背景情况:
- 视觉幻觉是帕金森病 (PD) 的一个常见的,使人虚弱的非运动症状.
- 这些幻觉与显著的负面结果有关,包括认知能力下降和死亡率增加.
- 目前对PD视觉幻觉的治疗选择有限.
研究的目的:
- 探索胆固醇系统功能障碍在帕金森病中视觉幻觉的发展中的作用.
- 提出一种神经生物学框架来理解这些幻觉.
- 根据胆固醇通路来确定潜在的治疗点.
主要方法:
- 对PD视觉幻觉神经生物学现有文献的综述.
- 对理论模型的分析,将认知过程与胆性神经传递联系起来.
- 综合证据表明中枢胆能系统退化.
主要成果:
- 汇聚的证据表明,中枢胆能系统的退化是视觉幻觉的重要因素.
- 胆固醇神经传递的变化会影响对感知至关重要的认知过程.
- 胆功能障碍可能为这些幻觉的复杂性提供一个统一的解释.
结论:
- 胆固醇神经生物学是理解帕金森病视觉幻觉的一个关键领域.
- 准胆固醇通路可能会改善PD中幻觉和精神病的治疗方法.
- 对个体病理生理学的进一步研究可以完善治疗策略.
相关概念视频
Parkinson's Disease: Treatment
237
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
237
Parkinson's Disease: Overview
498
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
498
Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.1K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.1K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
638
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
638
Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.2K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.2K
Cholinergic Antagonists: Therapeutic Uses
730
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
730


